Lumosa Therapeutics , Ltd. Accounts Payable

The latest accounts payable for 6535.TWO is $8.5M as of June 2026. That compares with $350K in the prior-year period — up 2315.4% year over year. Investors often review this figure alongside Lumosa Therapeutics , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 6535.TWO's accounts payable moved from $350K to $8.5M — a 2315.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lumosa Therapeutics , Ltd.'s operating scale or balance-sheet position.

A accounts payable figure of $8.5M for 6535.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 6535.TWO's accounts payable ($8.5M), review year-over-year change from $350K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Lumosa Therapeutics , Ltd.'s accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.